Illumina

Illumina

Yahoo Finance • 3 hours ago

Global Proteomic Biomarker Analytics Market: Five-Year Forecast by Application, Technology, Product, and End User | Double-Digit Growth Boosts Cancer Diagnostics and Drug Discovery

Company Logo New 307-page intelligence report maps surging demand for targeted omics technologies, profiling strategic moves by Danaher, Roche, and Thermo Fisher Scientific across global clinical landscapes. Dublin, Oct. 16, 2026 (GLOBE... Full story

Yahoo Finance • 22 hours ago

GTT Group Founder Michael Lubitz Joining Expert Panel at IAM Patent Transactions 2026 in San Diego

PORTLAND, Ore., Oct. 15, 2026 /PRNewswire/ -- Global Technology Transfer Group, Inc. (GTT Group), a market leader and pioneer in patent analysis, patent transactions, and patent enterprise value services, today announced that Senior Managi... Full story

Yahoo Finance • 3 days ago

Mammogen Appoints Diagnostics Industry Leader, Dr. Robert S. Epstein, to Board of Directors

Mammogen, Inc. Accomplished diagnostics and precision medicine leader brings decades of experience shaping the scientific, commercial and market success of category-defining companies across genomics, oncology and women's health NEWPORT... Full story

Yahoo Finance • 3 days ago

Global Chromosomal Microarray Reflex Testing Market Report 2026-2030 | Capitalize on 9.1% CAGR as Thermo Fisher, LabCorp, Illumina, Agilent, and Natera Scale Precision Genomics

Company Logo Dublin, Oct. 13, 2026 (GLOBE NEWSWIRE) -- "Chromosomal Microarray Reflex Testing Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global chromosomal microarray reflex testing market is expe... Full story

Yahoo Finance • 3 days ago

Illumina’s (ILMN) Sequencing Business Is Recovering, But Is the Stock Getting Ahead of Itself?

Illumina, Inc. (NASDAQ:ILMN) has returned 118% over the past six months, compared to a 21.25% return for the Insider Monkey Billionaire Indexand 14% for State Street SPDR S&P 500 ETF Trust. Illumina has given investors a reason to look at... Full story

Yahoo Finance • 4 days ago

3 Profitable Stocks We Steer Clear Of

3 Profitable Stocks We Steer Clear Of While profitability is essential, it doesn't guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, "Your margin is my... Full story

Yahoo Finance • 7 days ago

What is Illumina’s (ILMN) Economic Moat, and is it Widening or Narrowing?

Illumina, Inc. (NASDAQ:ILMN) traded at around $268 on October 7, down 2.11% on the day, though still 183.61% higher over twelve months. Revenue grew 9.40% in the most recent quarter while earnings fell 11.90%. A business selling more and... Full story

Yahoo Finance • 13 days ago

Moderna, Illumina lead healthcare gains in September as medtech drags

[Close-Up Shot of Scientists Hands typing Data in Laptop in Laboratory] Tom Werner Healthcare stocks underperformed the broader market in September, with the Health Care Select Sector SPDR Fund (XLV [https://seekingalpha.com/symbol/XLV])... Full story

Yahoo Finance • 21 days ago

Illumina (ILMN) Tests Valuation As Russell Index Removal Forces A Fresh Look

Index removal puts Illumina in focus Illumina (ILMN) has been removed from the Russell Small Cap Value Index, an index reshuffle that can prompt mechanical selling and raise fresh questions about how the stock is being valued today. The... Full story

Yahoo Finance • 23 days ago

Analysts Think 6 S&P 500 Stocks Are Grossly Overvalued

There's a joke on Wall Street that analysts never saw an S&P 500 stock they didn't like. Well, that doesn't seem to be the case now. Continue Reading... Full story

Yahoo Finance • 23 days ago

3 Healthcare Stocks with Warning Signs

3 Healthcare Stocks with Warning Signs From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare s... Full story

Yahoo Finance • 25 days ago

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

Biotech firms have been increasingly directing capital toward oncology therapeutics in recent years, reflecting a structural shift as companies recognize the significant commercial potential of precision oncology. According to BioPharma Di... Full story

Yahoo Finance • 30 days ago

Three Stocks Are Joining the S&P 500. Will They Actually Improve VOO’s Returns?

Quick Read VOO adds BE after its product revenue surged 215% on AI power demand, but new S&P entrants start below 0.1% of the index, barely moving returns. TTD exits as revenue growth cratered from 19% to 3%, while TAP leaves trading at j... Full story

Yahoo Finance • last month

Transcriptome Sequencing Market - Global Forecast to 2035; Bulk RNA-Seq Maintains Its Technology Market Lead

Company Logo The global transcriptome sequencing market is projected to reach $11.8 billion by 2035, growing at a 7.3% CAGR from 2025 to 2035. Growth is driven by falling sequencing costs, precision medicine, drug discovery, biomarker dev... Full story

Yahoo Finance • last month

Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now

Tandem Diabetes Care, Inc. TNDM is well-positioned to grow in the coming quarters driven by the expanding product choices. The company's pay-as-you-go reimbursement model could lower upfront barriers for pump starts and support higher supp... Full story

Yahoo Finance • last month

3 Stocks Soon Joining the S&P 500

The S&P 500 is set for another shakeup, with Bloom Energy BE, Everpure P, and Illumina ILMN all joining the widely followed index before the market opens on September 21st. Bloom Energy will replace Molson Coors Beverage, Everpure will re... Full story

Yahoo Finance • last month

The Zacks Analyst Blog Highlights FANUY, ABBNY, KYCCF, NVDA, ISRG, ILMN, NOVT, BOTZ, ROBO, ROBT and IBOT

For Immediate Release Chicago, IL – September 8, 2026 – Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the... Full story

Yahoo Finance • last month

Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?

Insulet PODD is well poised for growth in the upcoming quarters, owing to its strong momentum for the Omnipod 5 automated insulin delivery ("AID") system for both Type 1 and Type 2 populations. The company is strongly executing against its... Full story

Yahoo Finance • last month

Bloom Energy Joins the S&P 500 as The Trade Desk Leaves

This article first appeared on GuruFocus. Bloom Energy Corp. (NYSE:BE) rose 5.63% premarket after S&P Dow Jones Indices said it will join the S&P 500 before the open on September 21, part of the quarterly rebalance. Illumina Inc. (NASDAQ:... Full story

Yahoo Finance • last month

Bloom Energy Is Joining the S&P 500: Is the Stock Still a Buy After Its Massive Run?

Bloom Energy (NYSE: BE) stock has gone on an explosive run and has officially earned a spot in the S&P 500. On Sept. 4, S&P Dow Jones announced that Bloom Energy, along with Illumina and Everpure, would join the index, while Molson Coors,... Full story